CTOs on the Move

Catalyst OrthoScience

www.catalystortho.com

 
At Catalyst OrthoScience, our goal is to develop innovative medical solutions that make orthopedic surgery less invasive and more efficient for both surgeons and patients. Catalyst OrthoScience was founded by a board-certified orthopedic surgeon and is comprised of a team of biomedical industry professionals with more than 100 years of combined medical device experience. The Catalyst CSR Total Shoulder System is the result of the visionary insight of Steven Goldberg, M.D., a fellowship-trained orthopedic surgeon and shoulder specialist, who devised the next generation, higher precision, less-invasive total shoulder solution with a greatly simplified method of implant placement. The key design elements of ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Catalyst OrthoScience raised $12.7M on 05/14/2019

Similar Companies

Miltex

For more than 50 years, Miltex, Inc. has established itself as the largest and most respected supplier of hand-held surgical instruments in the alternate site market. Unique among its competitors, Miltex, Inc., through Miltex GmbH in Rietheim-Weiltheim,

Alliance Surgical Distributors

Alliance Surgical Distributors is a Redlands, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Omar Medical Supplies

Omar Medical Supplies is a University Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Logical Images

Logical Images is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

T2 Biosystems

At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.